Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.43 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846311 | 0.80 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL2847010 | 0.79 | GCG (0.47) | CNR1CNR2MCHR1 | |
| SCHEMBL2844359 | 0.78 | RAB9A (0.54) | CNR1CNR2 | |
| SCHEMBL3546576 | 0.76 | P2RX7 (0.37) | CNR1CNR2KCNH2P2RX7 | |
| SCHEMBL2841580 | 0.76 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL2843519 | 0.75 | RAB9A (0.53) | CNR1 | |
| SCHEMBL2844282 | 0.75 | CNR1 (0.46) | CNR1 | |
| SCHEMBL2840753 | 0.74 | HPGD (0.42) | CNR1CNR2P2RX7 | |
| SCHEMBL2839856 | 0.74 | LMNA (0.44) | CNR1ALDH1A1 | |
| SCHEMBL2846413 | 0.73 | CNR1 (0.42) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | claimed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | claimed |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885DRD2 107/4885 |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885DRD2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.